Norris Comprehensive Cancer Center and Hospital, Keck School of Medicine, University of Southern California, Los Angeles, CA.
Division of Hematology, Keck School of Medicine, University of Southern California, Los Angeles, CA.
Hepatology. 2019 Jun;69(6):2652-2663. doi: 10.1002/hep.30557. Epub 2019 Apr 9.
Telomeres are repetitive DNA sequences that protect the ends of linear chromosomes, and they are maintained by a ribonucleoprotein complex called telomerase. Variants in genes encoding for telomerase components have been associated with a spectrum of disease in the lung, skin, bone marrow, and liver. Mutations in the telomerase reverse transcriptase and telomerase RNA component genes have been observed at a higher prevalence in patients with liver disease compared with the general population; however, the presence of variants in other components of the telomerase complex and their impact on clinical outcomes has not been explored. We evaluated 86 patients with end-stage liver disease for variants in an expanded panel of eight genes, and found that 17 patients (20%) had likely deleterious variants by in silico analysis. Seven unique likely deleterious variants were identified in the regulator of telomere elongation helicase 1 (RTEL1) gene that encodes for a DNA helicase important in telomere maintenance and genomic stability. In gene burden association analysis of their clinical data, the presence of any RTEL1 variant was associated with a 29% lower baseline white blood cell count (95% confidence interval [CI], -7% to -46%; P Value = 0.01) compared with patients without RTEL1 variants, and the presence of any exonic missense RTEL1 variant was associated with a 42% lower baseline platelet count (95% CI, -5% to -65%: P Value = 0.03). The presence of any telomerase variant was associated with an increased number of readmissions within 1 year after transplantation demonstrated by an incident rate ratio (IRR) of 3.15 (95% CI, 1.22 to 8.57). No association with survival was observed. Conclusion: Among patients who underwent liver transplantation, the presence of any exonic missense variant was associated with a longer postoperative length of stay with an IRR of 2.16 (95% CI, 1.31 to 3.68).
端粒是保护线性染色体末端的重复 DNA 序列,它们由一种称为端粒酶的核糖核蛋白复合物维持。编码端粒酶成分的基因中的变体与肺部、皮肤、骨髓和肝脏的一系列疾病有关。与普通人群相比,患有肝病的患者中观察到端粒酶逆转录酶和端粒酶 RNA 成分基因的突变更为普遍;然而,端粒酶复合物的其他成分中的变体及其对临床结果的影响尚未得到探索。我们评估了 86 例终末期肝病患者的 8 个基因扩展面板中的变体,发现 17 例(20%)患者通过计算机分析存在可能的有害变体。在端粒延长解旋酶 1(RTEL1)基因中发现了 7 种独特的可能有害变体,该基因编码一种在端粒维持和基因组稳定性中起重要作用的 DNA 解旋酶。在对其临床数据进行基因负担关联分析时,与没有 RTEL1 变体的患者相比,任何 RTEL1 变体的存在与基线白细胞计数降低 29%相关(95%置信区间,-7%至-46%;P 值=0.01),任何外显子错义 RTEL1 变体的存在与基线血小板计数降低 42%相关(95%置信区间,-5%至-65%:P 值=0.03)。任何端粒酶变体的存在与移植后 1 年内再入院次数的增加相关,通过发生率比(IRR)为 3.15(95%置信区间,1.22 至 8.57)来证明。未观察到与生存相关。结论:在接受肝移植的患者中,任何外显子错义变体的存在与术后住院时间延长相关,发生率比(IRR)为 2.16(95%置信区间,1.31 至 3.68)。